Literature DB >> 26206736

Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients.

Janice Y Chyou1, Tina D Hunter2, Sarah A Mollenkopf3, Mintu P Turakhia4, Matthew R Reynolds5.   

Abstract

BACKGROUND: The incremental effects of risk factor combinations for atrial fibrillation (AF) and stroke are incompletely understood. We sought to quantify the risks of incident AF and stroke for combinations of established risk factors in a large US sample. METHODS AND
RESULTS: Patients with no evidence of AF or stroke in 2007 were stratified by combinations of the following risk factors: heart failure, hypertension, diabetes, age 65 to 74, age ≥75, coronary artery disease, and chronic kidney disease. Patients with ≥2 of the first 5 or ≥3 of the first 7, classified as "high-risk," and an age-matched sample of patients with fewer risk factors, classified as "low-risk," were followed over 2008-2010 for incident AF and stroke. Annualized incidence rates and risks were quantified for each combination of factors by using Cox regression. Annualized incidence rates for AF, stroke, and both were 3.59%, 3.27%, and 0.62% in 1 851 653 high-risk patients and 1.32%, 1.48%, and 0.18% in 1 156 221 low-risk patients, respectively. Among patients with 1 risk factor, those with age ≥75 had the highest hazards of incident AF and stroke (HR 9.2, 6.9). Among patients with 2 risk factors, those with age ≥75 and heart failure had the highest annualized incidence rates of AF and stroke (10.2%, 5.9%). The combination of age ≥75 and hypertension was prevalent and had the highest incidences of AF and stroke.
CONCLUSIONS: Adults with combinations of known risk factors are at increased risk of incident AF and stroke, but combinations of risk factors are not always additive.
© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Entities:  

Keywords:  atrial fibrillation; epidemiology; risk factors/global assessment; risk stratification; stroke

Mesh:

Year:  2015        PMID: 26206736      PMCID: PMC4608064          DOI: 10.1161/JAHA.114.001723

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


Atrial fibrillation (AF), the most common cardiac arrhythmia, is projected to affect nearly 3 million people in the United States by 2015.1 AF increases stroke risk by 5-fold; this risk is further modified by the presence of other stroke risk factors.2 Although oral anticoagulant drugs significantly reduce the risk of stroke in patients diagnosed with AF, it is not uncommon for AF to be detected only after the occurrence of a stroke, even when symptoms likely indicative of arrhythmias are present.3–5 While risk factors and risk stratification schemas for AF6,7 and for stroke7–11 have been reported from epidemiologic data, the assessment of risk based on specific combinations of known risk factors have not been previously reported. The incremental risks of various factors in different combinations may not be additive; thus, different combinations with the same number of risk factors may confer very different total risks for the development of AF or stroke. However, analyzing a large number of potential risk factor combinations requires a very large sample size and thus is not feasible with most sources of clinical data. Therefore, the objective of our study was to use a large healthcare claims database to quantify and stratify the total and incremental risks associated with combinations of risk factors for AF and stroke in a large sample of the US population.

Methods

Study Design

We conducted a retrospective cohort study by using health care claims data from the Truven Health MarketScan Commercial and Medicare Supplemental Databases (January 2007 to December 2010). These databases represent the health services of >180 million employees, dependents, and retirees in the United States with primary or Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or capitated health plans. These databases consist of fully integrated patient-level records that serve as the basis of >350 peer-reviewed articles since 2000 and are fully HIPAA compliant.12,13 In particular, these data have been used extensively for outcomes research related to AF and stroke risk.14–17 A protocol describing the study objectives, criteria for patient selection, data elements of interest, and statistical methods was submitted to the New England Institutional Review Board (NEIRB) and exemption was obtained (NEIRB No. 12-388).

Study Population

The study population consisted of all patients in the MarketScan databases with continuous medical and pharmacy enrollment for the entire baseline calendar year of 2007 and with no record of AF or stroke diagnoses in either inpatient or outpatient claims during that time (Appendix S1). For the purposes of this study, stroke diagnoses included both ischemic and hemorrhagic strokes, as well as transient ischemic attack (TIA). The study cohort was classified according to the following 7 epidemiologically determined risk factors known to be associated with AF and/or stroke: (1) heart failure, (2) hypertension, (3) diabetes, (4) age ≥65 to 74 years, (5) age ≥75 years, (6) coronary artery disease (CAD), and (7) chronic kidney disease (CKD).18 Baseline risk factors were identified by using claims data from calendar year of 2007 (Appendix S2). Any patient with ≥2 of the first 5 risk factors or ≥3 of any of the 7 risk factors was defined as high risk for future AF or stroke and was assigned to the high-risk cohort. These 7 factors were selected based on epidemiologic data and previous risk prediction models for AF1,6,7,19–21 and for stroke.8,9,22,23 The threshold of 2 or 3 factors corresponds roughly with pre-2014 guidelines for oral anticoagulation of AF patients with high risk of stroke.24 To create a low-risk cohort for comparison, a random-number generator was used to draw samples of patients in a 1:1 ratio from among the patients with lower risk profiles, matched by age group to the high-risk cohort (Figure1).
Figure 1

Study population. The eligible population included 18.8 million patients without AF or stroke diagnoses in 2007. From these, a high-risk cohort of 1.85 million patients and an age-matched low-risk cohort of 1.16 million patients were identified and included in our study. The multivariable analysis population included both the high-risk and the age-matched low-risk cohort, totaling ≈3.01 million patients. AF indicates atrial fibrillation.

Study population. The eligible population included 18.8 million patients without AF or stroke diagnoses in 2007. From these, a high-risk cohort of 1.85 million patients and an age-matched low-risk cohort of 1.16 million patients were identified and included in our study. The multivariable analysis population included both the high-risk and the age-matched low-risk cohort, totaling ≈3.01 million patients. AF indicates atrial fibrillation. All patients in the high-risk and age-matched low-risk cohorts were included in the multivariable analysis population (Figure1). Each patient in this population, regardless of risk cohort designation, was further classified by their distinct combination of the 7 baseline risk factors, by using a categorical variable with 96 values to represent the full spectrum of mutually exclusive and collectively exhaustive risk factor combinations.

Identification of Outcomes

The outcomes for this study were incident AF and incident stroke (ischemic, hemorrhagic, and TIA), as defined with International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes (Appendix S1). Diagnoses of AF and stroke were tracked for patients with continuous enrollment extending through any portion of calendar years 2008–2010. Incidence rates during the 3 years of follow-up were calculated and annualized for the entire population by dividing the total counts of patients with each event by the sum of patient-years to the first of either the patient’s index event or enrollment censoring date. Annualized incidence rates were calculated for the high-risk and low-risk cohorts, for each combination of sex and age group (ages 0 to 17, 18 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 74, and ≥75 years), as well as for each of the 96 risk factor combinations in the multivariable analysis population.

Statistical Analysis

We calculated hazard ratios (HRs) for incident AF and incident stroke during the 3-year follow-up period from January 1, 2008, to December 31, 2010, by using Cox regression models. All patients with enrollment through December 31, 2010, were censored as of that date. For each end point (AF or stroke/TIA), 2 models were constructed. All analyses were performed with SAS Version 9.2 (SAS Institute). The first set of Cox regression models used individual baseline risks as predictor variables, such that HRs for each risk could be calculated, with adjustment for all remaining risks and other baseline characteristics. Values for individual baseline predictor variables were obtained from the claims databases. Predictor variables were age group, sex, geographic region, comorbid conditions (heart failure, hypertension, diabetes, CAD, CKD, and sleep apnea, identified based on ICD-9 codes and prescription medications as described in Appendix S2), symptoms (chest pain, palpitations, dizziness, tachycardia, and respiratory abnormalities, identified based on ICD-9 codes as described in Appendix S3), baseline medication use, and use of internal cardiac devices (pacemaker, implantable cardioverter-defibrillator, implantable loop recorder) or external electrocardiographic monitoring (Holter, external loop monitor, mobile cardiac outpatient telemetry). In addition to these predictors, the stroke model adjusted for oral anticoagulation use >14 days before stroke event or censoring date and for the diagnosis of incident AF before or concurrent with stroke event. Patients with none of the studied risk factors were used as the reference group. The second set of multivariable models evaluated the incremental impact of individual risks within risk factor combinations. This was accomplished by creating Cox regression models for AF and stroke that used a single categorical predictor variable denoting each patient’s mutually exclusive and collectively exhaustive risk factor combination. Patients with none of the studied risk factors were used as the reference group for this model.

Results

Patient Population

Of the 19 173 907 patients in the source population with continuous medical and pharmacy enrollment throughout 2007 in the Truven Health MarketScan Commercial and Medicare Supplemental Databases, 366 445 (1.9%) were excluded based on a diagnosis of AF and/or stroke at baseline. From the remaining population of 18 807 462 patients, a high-risk cohort of 1 851 653 (9.8%) patients was identified. A total of 1 156 221 lower-risk patients were randomly selected from within each age group to match the age distribution of the high-risk cohort. The sampling ratio was 1:1 except in age groups ≥65 years, where age itself was a predefined risk factor and thus fewer low-risk patients were available. The combined multivariable analysis population consisted of 3 007 874 patients (Figure1). Baseline characteristics of the overall analysis population and the 2 risk cohorts are summarized in Table1. Among the high-risk patients, the most prevalent risk factors were hypertension (95.3%), diabetes (52.9%), and age ≥65 years (66.0%). Only a small proportion of patients with symptoms commonly associated with cardiac arrhythmias had external cardiac monitoring, regardless of risk cohort designation (Table1). There are additional baseline characteristics in Appendix S4.
Table 1

Baseline Characteristics of Analysis Population: High-Risk Cohort and Low-Risk Cohort as Well as Combined Population for Multivariable Analysis

Baseline CharacteristicsHigh-Risk Cohort (n=1 851 653), No. (%)Low-Risk Cohort (n=1 156 221), No. (%)Combined Population (N=3 007 874), No. (%)
Age group, y
 0 to 171304 (0.1)1304 (0.1)2608 (0.1)
 18 to 3420 463 (1.1)20 463 (1.8)40 926 (1.4)
 35 to 4467 962 (3.7)67 962 (5.9)135 924 (4.5)
 45 to 54205 934 (11.1)205 934 (17.8)411 868 (13.7)
 55 to 64333 810 (18.0)333 810 (28.9)667 620 (22.2)
 65 to 74643 258 (34.7)319 014 (27.6)962 272 (32.0)
 ≥75578 922 (31.3)207 734 (18.0)786 656 (26.2)
Sex
 Male862 486 (46.6)556 212 (48.1)1 418 698 (47.2)
 Female989 167 (53.4)600 009 (51.9)1 589 176 (52.8)
Comorbid conditions used for risk stratification
 Heart failure138 746 (7.5)505 (0.0)139 251 (4.6)
 Hypertension1 764 318 (95.3)186 868 (16.2)1 951 186 (64.9)
 Diabetes978 724 (52.9)28 295 (2.5)1 007 019 (33.5)
 Coronary artery disease331 185 (17.9)43 649 (3.8)374 834 (12.5)
 Chronic kidney disease93 034 (5.0)6058 (0.5)99 092 (3.3)
Comorbid condition not used for risk stratification
 Sleep apnea107 000 (5.8)26 691 (2.3)133 691 (4.4)
Symptoms
 Any symptom517 646 (28.0)153 721 (13.3)671 367 (22.3)
 Chest pain312 300 (16.9)86 924 (7.5)399 224 (13.3)
 Dizziness87 437 (4.7)27 982 (2.4)115 419 (3.8)
 Palpitations49 033 (2.7)17 374 (1.5)66 407 (2.2)
 Tachycardia unspecified15 641 (0.8)3295 (0.3)18 936 (0.6)
 Shortness of breath165 614 (8.9)34 918 (3.0)200 532 (6.7)
 Respiratory—other104 711 (5.7)23 084 (2.0)127 795 (4.2)
 Respiratory—unspecified10 836 (0.6)2476 (0.2)13 312 (0.4)
External cardiac monitoring
 Overall27 303 (1.5)6140 (0.5)33 443 (1.1)
 Among patients with any symptom22 433 (4.3)5046 (3.3)27 479 (4.1)

Baseline characteristics are based on records from the Truven Health MarketScan® Commercial and Medicare Supplemental Databases from the calendar year of 2007. y indicates years.

Baseline Characteristics of Analysis Population: High-Risk Cohort and Low-Risk Cohort as Well as Combined Population for Multivariable Analysis Baseline characteristics are based on records from the Truven Health MarketScan® Commercial and Medicare Supplemental Databases from the calendar year of 2007. y indicates years.

Annualized Incidence Rates and Risk Cohorts

Risk cohort designation, based on our risk stratification scheme of baseline risk factors, differentiated patients with high-risk for incident AF, incident stroke, or both AF and stroke from low-risk patients. The annualized incidence rates for AF alone, stroke alone, and both AF and stroke were 3.59%, 3.27%, and 0.62% for the high-risk cohort and 1.32%, 1.48%, and 0.18%, respectively, for the low-risk cohort (Table2).
Table 2

Annualized Incidence of Atrial Fibrillation, Stroke, and Both Atrial Fibrillation and Stroke

Event Category (2008–2010)High-Risk Cohort (n=1 851 653)Low-Risk Cohort (n=1 156 221)Combined Population (N=3 007 874)
Annualized IncidencePatientsRate/yPatientsRate/yPatientsRate/y
Atrial fibrillation134 4953.59%31 2461.32%165 7412.71%
Stroke123 0533.27%34 9671.48%158 0202.58%
Both atrial fibrillation and stroke23 9710.62%44240.18%28 3950.45%

Annualized incidence rate is derived by dividing patient counts by total patient-years.

Annualized Incidence of Atrial Fibrillation, Stroke, and Both Atrial Fibrillation and Stroke Annualized incidence rate is derived by dividing patient counts by total patient-years.

Annualized Incidence Rates Stratified by Age, Sex, and Risk Cohort Designation

In the multivariable analysis population, composed of both the high- and low-risk cohorts, annualized AF and stroke rates were stratified by combination of age group, sex, and high-/low-risk cohort. Among these combinations, rates of incident AF and incident stroke appeared to increase exponentially with each age group, regardless of sex or risk cohort stratification (Figure2A and 2B). Annualized incidence rates for AF were higher in men than in women in all age groups, except in the 0 to 17 age group, where the incidence rates in both men and women were very low (Figure2A). However, annualized incidence rates for stroke were similar across the sexes (Figure2B).
Figure 2

A, Annualized incidence rates of atrial fibrillation stratified by age, sex, and risk cohort, unadjusted, 2008–2011. B, Annualized incidence rates of stroke stratified by age, sex, and risk cohort, unadjusted, 2008–2011.

A, Annualized incidence rates of atrial fibrillation stratified by age, sex, and risk cohort, unadjusted, 2008–2011. B, Annualized incidence rates of stroke stratified by age, sex, and risk cohort, unadjusted, 2008–2011.

Relationship Between Incident AF and Incident Stroke in Patients Diagnosed With Both Incident AF and Incident Stroke in the Follow-up Period

In the combined population, 158 020 patients were diagnosed with stroke in the follow-up period. Diagnoses of incident AF were also reported for 28 395 (18%) of these patients with incident stroke. Among the patients with diagnoses of both AF and stroke in the follow-up period, diagnosis of incident AF was most commonly within 14 days of stroke diagnosis, followed by >14 days after stroke diagnosis, and was least likely to occur >14 days before stroke diagnosis (Figure3).
Figure 3

Timing of diagnosis of incident AF in relation to diagnosis of incident stroke. Of those with diagnosis of both incident AF and incident stroke in, diagnosis of AF was most commonly within 14 days of diagnosis of incident stroke. AF indicates atrial fibrillation.

Timing of diagnosis of incident AF in relation to diagnosis of incident stroke. Of those with diagnosis of both incident AF and incident stroke in, diagnosis of AF was most commonly within 14 days of diagnosis of incident stroke. AF indicates atrial fibrillation.

Hazard Ratios of Individual Risk Factors for Incident AF and for Incident Stroke Based on Multivariable Analysis

In the first multivariable Cox regression models, HRs for incident AF and for incident stroke were calculated by using individual risk factors as independent variables. As summarized in Table3, the risk for incident AF and for incident stroke both increased exponentially with age. Male sex was a significant predictor of incident AF but not of stroke. Comorbid conditions and symptoms each individually conferred modest but significant risks for incident AF as well as stroke. In the stroke model, diagnosis of incident AF >14 days before or within 14 days of the censoring date (the first of a stroke event or end of follow-up) dramatically increased risks of stroke, whereas oral anticoagulation use >14 days before the censoring date significantly decreased risks for stroke.
Table 3

Multivariable Hazard Ratios of Individual Risk Factors for Incident Atrial Fibrillation (AF) or Incident Stroke Based on Cox Regression Models

AF*Stroke*
Hazard RatioP ValueHazard RatioP Value
Predictor variable
 Age group, y (reference = 18 to 34 years)
  35 to 441.300.00101.54<0.0001
  45 to 542.40<0.00012.41<0.0001
  55 to 644.65<0.00013.99<0.0001
  65 to 748.19<0.00016.56<0.0001
  ≥7516.37<0.000110.82<0.0001
 Sex (reference = Female)
  Male1.32<0.00010.990.0765
 Comorbid conditions used for risk stratification of cohorts, 2007 (reference=no)
  Heart failure1.72<0.00011.23<0.0001
  Hypertension1.31<0.00011.24<0.0001
  Diabetes1.11<0.00011.25<0.0001
  Coronary artery disease1.21<0.00011.04<0.0001
  Chronic kidney disease1.23<0.00011.26<0.0001
 Comorbid condition not used for risk stratification of cohorts, 2007 (reference=no)
  Sleep apnea1.21<0.00011.14<0.0001
 Symptoms
  Chest pain1.010.04111.27<0.0001
  Dizziness1.07<0.00011.40<0.0001
  Palpitations1.46<0.00011.07<0.0001
  Tachycardia unspecified1.19<0.00011.13<0.0001
  Shortness of breath1.16<0.00011.13<0.0001
  Respiratory—other1.01<0.00011.12<0.0001
  Respiratory—unspecified1.090.62921.090.0033
 Indicators of stroke timing (reference=no)
  AF event >14 d before stroke event16.2<0.0001
  AF event within 14 d of stroke event21.9<0.0001
  Oral anticoagulation use >14 d before stroke event0.6<0.0001

d indicates days; y, years.

Estimates for each risk factor were adjusted for geographic region, medications, and use of internal/external electrocardiographic recording devices, in addition to all other risk factors shown in the table.

Stroke model also included indicators of stroke timing.

Multivariable Hazard Ratios of Individual Risk Factors for Incident Atrial Fibrillation (AF) or Incident Stroke Based on Cox Regression Models d indicates days; y, years. Estimates for each risk factor were adjusted for geographic region, medications, and use of internal/external electrocardiographic recording devices, in addition to all other risk factors shown in the table. Stroke model also included indicators of stroke timing.

Annualized Incidence Rates and Hazard Ratios of Unique Risk Combinations for Incident AF and for Incident Stroke

Annualized risks were calculated for each mutually exclusive and collectively exhaustive combination of risk factors. Hazard ratios were calculated separately for incident AF and stroke for each of the 96 unique risk factor combinations by using Cox regression models with a single predictor variable that categorized patients according to their baseline combination. Patients with none of the studied risk factors were used as the reference group. Annualized incidence rates, HRs, p-value levels, event counts, and sample sizes for all 96 risk factor combinations are summarized in Table4. The most prevalent high-risk combinations were hypertension plus age 65 to 74 and hypertension plus diabetes.
Table 4

Annualized Incidence Rates and HRs of All Unique Risk Combinations for Incident AF and for Incident Stroke

Risk FactorsSample Size (2007)Stroke IncidenceAF Incidence
Diagnoses (2008–10)Annualized Rate* (%/year)HRDiagnoses (2008–10)Annualized Rate* (%/year)HR
Cohort with no risk factors
 None409 07439690.5Ref29000.4Ref
Cohorts with single risk factors
 Age 65 to 74305 98410 8981.63.3****88401.33.7****
 Age 75+195 12013 2943.36.9****12 9583.29.2****
 HTN168 93233361.02.1****31140.92.6****
 Diabetes27 0255251.02.0****3460.61.8****
 CAD41341231.63.3****891.13.2****
 CKD563191.83.6****90.82.3*
 HF414172.24.5****131.74.7****
Cohorts with 2 risk factors
 HTN+diabetes490 92413 0361.32.8****96401.02.8****
 HTN+age 65 to 74338 40217 0712.34.7****17 6662.46.8****
 HTN+age 75+298 56028 9684.79.6****32 2685.314.8****
 Diabetes+age 65 to 7441 69722432.45.0****16001.74.9****
 Diabetes+age 75+25 02524804.89.9****21384.111.6****
 HF+HTN17 4276822.14.4****11813.810.6****
 HTN+CAD15 8355551.94.0****5942.15.8****
 CAD+age 65 to 7411 6796572.75.5****6932.88.0****
 CAD+age 75+10 88511475.310.8****12815.916.7****
 HF+age 75+36723425.912.1****56510.228.6****
 HTN+CKD2101932.44.8****631.64.5****
 CKD+age 75+17291745.411.1****2066.518.2****
 HF+diabetes1443572.24.5****622.46.8****
 CKD+age 65 to 741351903.26.6****953.49.5****
 HF+age 65 to 741279923.77.6****1335.515.4****
 Diabetes+CAD1005543.06.2****301.64.6****
 Diabetes+CKD265143.06.2****122.67.2****
 HF+CAD7621.53.021.54.2*
 CAD+CKD3500.00.011.74.7
 HF+CKD1400.00.000.00.0
Cohorts with 3 risk factors
 HTN+diabetes+age 65 to 74114 73077113.16.4****72702.98.2****
 HTN+diabetes+age 75+79 59788055.411.1****92175.716.0****
 HTN+CAD+age 75+65 20076605.811.9****99957.821.8****
 HTN+diabetes+CAD62 43329762.65.4****27792.46.9****
 HTN+CAD+age 65 to 7461 47844713.47.1****54904.312.0****
 HTN+diabetes+CKD16 3809423.16.4****7332.46.8****
 HF+HTN+age 75+16 33919617.014.4****325512.434.8****
 HTN+CKD+age 75+11 64113375.912.2****15456.919.5****
 HF+HTN+diabetes97086183.67.5****7874.713.1****
 HF+HTN+CAD86434463.06.2****7825.415.1****
 HTN+CKD+age 65 to 7479186373.87.9****5833.59.8****
 HF+HTN+age 65 to 7466575684.38.8****9887.821.8****
 Diabetes+CAD+age 65 to 7435512933.98.1****2613.59.9****
 Diabetes+CAD+age 75+28893506.112.5****4117.220.3****
 HTN+CAD+CKD26751703.77.7****1663.610.2****
 HF+HTN+CKD13671155.210.7****1185.314.9****
 HF+diabetes+age 75+11351196.413.2****1769.827.5****
 HF+CAD+age 75+10291318.016.4****20613.437.5****
 Diabetes+CKD+age 65 to 74830824.910.1****774.613.0****
 Diabetes+CKD+age 75+7921026.914.2****916.117.1****
 HF+diabetes+age 65 to 74567595.511.3****908.824.8****
 HF+CAD+age 65 to 74379223.06.2****497.120.0****
 HF+diabetes+CAD353284.79.6****294.713.3****
 CAD+CKD+age 75+289336.413.2****418.223.2****
 HF+CKD+age 75+2333110.521.7****3813.437.2****
 Diabetes+CAD+CKD222154.18.4****123.29.1****
 CAD+CKD+age 65 to 7413993.16.3****155.415.1****
 HF+diabetes+CKD11484.79.6****158.724.3****
 HF+CKD+age 65 to 744834.08.2***45.515.3****
 HF+CAD+CKD3347.415.2****715.041.9****
Cohorts with 4 risk factors
 HTN+diabetes+CAD+age 65 to 7431 77429404.49.1****32734.913.9****
 HTN+diabetes+CAD+age 75+24 61432716.713.7****38718.022.6****
 HF+HTN+CAD+age 75+11 27015387.816.0****264014.440.5****
 HF+HTN+diabetes+CAD78866084.79.6****8706.819.1****
 HF+HTN+diabetes+age 75+724310268.417.2****149412.735.7****
 HTN+diabetes+CKD+age 65 to 7471617325.010.2****6924.713.2****
 HTN+diabetes+CKD+age 75+61898447.114.7****8687.420.8****
 HF+HTN+CAD+age 65 to 7453995565.210.8****9489.426.5****
 HF+HTN+diabetes+age 65 to 7448015235.611.5****7698.524.0****
 HTN+diabetes+CAD+CKD43843965.310.9****3504.613.0****
 HTN+CAD+CKD+age 75+42125747.214.8****7459.627.0****
 HTN+CAD+CKD+age 65 to 7423332505.210.7****2876.117.1****
 HF+HTN+diabetes+CKD23042125.912.1****2376.618.6****
 HF+HTN+CKD+age 75+20592507.916.3****43014.540.5****
 HF+HTN+CKD+age 65 to 74697826.713.7****11810.028.0****
 HF+HTN+CAD+CKD693595.711.7****10210.529.5****
 HF+diabetes+CAD+age 75+4216810.822.2****8413.437.4****
 HF+diabetes+CAD+age 65 to 74260316.513.4****418.924.9****
 Diabetes+CAD+CKD+age 75+188297.916.3****246.618.6****
 Diabetes+CAD+CKD+age 65 to 74178175.110.5****247.521.1****
 HF+diabetes+CKD+age 75+145126.012.4****2915.342.8****
 HF+CAD+CKD+age 75+9721.53.02521.560.0****
 HF+diabetes+CKD+age 65 to 748053.98.0****2118.251.0****
 HF+diabetes+CAD+CKD6955.210.8****99.927.7****
 HF+CAD+CKD+age 65 to 742900.00.0512.635.2****
Cohorts with 5 risk factors
 HF+HTN+diabetes+CAD+age 75+652610008.918.4****143413.437.7****
 HF+HTN+diabetes+CAD+age 65 to 7453086756.713.8****99510.329.0****
 HTN+diabetes+CAD+CKD+age 65 to 7433304086.212.7****4506.819.2****
 HTN+diabetes+CAD+CKD+age 75+31724437.415.3****64711.331.8****
 HF+HTN+diabetes+CAD+CKD24152728.016.4****3149.225.7****
 HF+HTN+CAD+CKD+age 75+20382959.519.5****47316.345.7****
 HF+HTN+diabetes+CKD+age 75+18752789.720.0****40414.941.7****
 HF+HTN+diabetes+CKD+age 65 to 7414291957.916.2****25010.328.8****
 HF+HTN+CAD+CKD+age 65 to 74694816.814.0****14513.136.7****
 HF+diabetes+CAD+CKD+age 75+901410.621.9****2419.153.4****
 HF+diabetes+CAD+CKD+age 65 to 745956.012.3****1014.239.5****
Cohort with 6 risk factors
 HF+HTN+diabetes+CAD+CKD+age 75+238236910.321.3****51015.041.9****
 HF+HTN+diabetes+CAD+CKD+age 65 to 7420513119.218.9****40012.134.0****

Each section is displayed in descending order of HR for AF or stroke. HR indicates hazard ratio; AF, atrial fibrillation; HTN, hypertension; CAD, coronary artery disease; CKD, chronic kidney disease; HF, heart failure.

Unadjusted annualized incidence rate.

HRs were calculated by using the second Cox regression model with mutually exclusive and collectively exhaustive risk factor combination as a predictor and patients with none of the studied risk factors were used as the reference group.

P<0.05

P<0.01

P<0.001

P<0.0001.

Annualized Incidence Rates and HRs of All Unique Risk Combinations for Incident AF and for Incident Stroke Each section is displayed in descending order of HR for AF or stroke. HR indicates hazard ratio; AF, atrial fibrillation; HTN, hypertension; CAD, coronary artery disease; CKD, chronic kidney disease; HF, heart failure. Unadjusted annualized incidence rate. HRs were calculated by using the second Cox regression model with mutually exclusive and collectively exhaustive risk factor combination as a predictor and patients with none of the studied risk factors were used as the reference group. P<0.05 P<0.01 P<0.001 P<0.0001. Annualized rates of AF and stroke diagnoses among patients with no risk factors were 0.35% and 0.49%, respectively, while rates ranged from 0.65% to 3.34% for those with single risk factors (Figure4). Among patients with a single risk factor, patients with age ≥75 had the highest risks of AF (annualized incidence rate of 3.25%, HR 9.2) and highest risks of stroke (annualized incidence rate of 3.34%, HR 6.9) (Figure4 and Table4). Among patients with 2 risk factors, those with age ≥75 in combination with HF had the highest annualized incidence rate for AF and for stroke (10.2% and 5.9%, respectively), and the annualized incidence rates for AF were supra-additive (exceeding summation of 3.2% for age ≥75 alone and 1.7% for heart failure alone) (Table4). The estimate of excess risk attributable to the interaction of these 2 risk factors is 5.3%, which is highly statistically significant due to the large sample sizes within each of these risk factor cohorts.
Figure 4

Annualized incidence rates of AF and stroke diagnoses for patients with no risk factors or a single risk factor. AF indicates atrial fibrillation; CAD, coronary artery disease; HF, heart failure; HTN, hypertension.

Annualized incidence rates of AF and stroke diagnoses for patients with no risk factors or a single risk factor. AF indicates atrial fibrillation; CAD, coronary artery disease; HF, heart failure; HTN, hypertension. As illustrated in Table4, risks for incident AF and for incident stroke did not increase linearly with the number of risk factors, and not all risk factor combinations conferred equal risks. Combinations inclusive of heart failure, hypertension, or age ≥75 appear to confer the highest risks for incident AF or incident stroke among 2–, 3–, 4–, 5–, or 6–risk factor combinations. The single risk factor of age ≥75 conferred greater risks for incident AF and for incident stroke than did 2–risk factor combinations of hypertension with age 65 to 74, or diabetes with age, or hypertension with diabetes. Similarly, among the 2–risk factor combinations, the combination group with age ≥75 and hypertension had greater risks for incident AF and for incident stroke than 3–risk factor combinations of hypertension with CAD and age 65 to 74 or hypertension with diabetes and age 65 to 74, or hypertension with diabetes and CAD. Furthermore, the prevalence of risk factor combinations in the population at baseline contributes to overall incidences of AF and stroke. Because age ≥75 was a prevalent risk factor, patients with age ≥75, as a single risk factor or in combination with additional risk factors, accounted for large numbers of AF and stroke events. In particular, the combination of age ≥75 and hypertension (298 560 patients) had the highest absolute numbers of incident AF (32 268 diagnoses, HR 14.83) and incident stroke (28 968 diagnoses, HR 9.64) events. The HRs computed in this analysis used the healthiest cohort (ie, patients with no risk factors) as the reference group. However, because all of these ratios were computed by using the same reference, the HR for any risk cohort compared with any other risk cohort can be estimated from the results in Table4 by simply dividing the HR for the cohort of interest by the HR for the reference group of interest. For instance, if it is more desirable to compare the stroke risk for a patient of age 65 to 74 with diabetes to a patient of the same age without diabetes, the HR associated with the added risk of diabetes could be calculated as 5.0/3.3=1.5.

Discussion

In this study of >3 million US patients, for the first time, we quantified the separate and combinatorial effects of individual risk factors for incident AF and incident stroke by using a large claims database. In our stratification system, patients classified as high risk based on the presence of a combination of heart failure, hypertension, diabetes, advanced age (65 to 74 or ≥75 years), CAD, and CKD were indeed at higher risk for incident AF and incident stroke. These findings are consistent with epidemiologic data and previous risk prediction models for AF1,6,7,19–21 and for stroke,8,9,22,23 validating the concept that comorbidities determined from a claims database may provide reasonably accurate risk prediction. Male sex was a significant predictor of incident AF in our study. This is consistent with published data from the Framingham Heart Study,6 the Atherosclerosis Risk in Communities Study,23 and the Cardiovascular Health Study.20 Sex was not, however, a significant predictor of all-cause stroke in our study. This is not inconsistent with published data; although existing models (CHA2DS2-VASc, Framingham Heart Study) have demonstrated an independent association between female sex and stroke in the particular setting of AF, sex is not an independent predictor of all-cause stroke in the Framingham Heart Study model.22 The large size of our sample provided statistical power to compare risks associated with specific factors, not only in isolation but also in various combinations. With this approach, we demonstrated that not all risk factors—or risk factor combinations—are “created equal.” Age ≥75 was the single most important risk factor for both incident AF and incident stroke, whether in isolation or in combination with other factors. Combinations of risk factors that included heart failure, hypertension, or age ≥75 conferred the highest risk for incident AF and incident stroke. Furthermore, we showed that risk factors are not simply additive—despite the convenience of certain existing models, 1 plus 1 does not always equal 2. For example, when combined, the risks of age ≥75 and heart failure were supra-additive, exceeding the sum of the risks associated with each factor in isolation. The most recently revised AF guideline from the American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society highlights clinical risk factors associated with increased risks for AF but has not incorporated risk assessment schema for the identification and management of patients at risk for AF.25 As the management of common cardiovascular conditions (eg, heart failure and ischemic heart disease) has moved to a stratified approach, based on risk level, we anticipate the management of AF and stroke to follow this similarly expanded framework. Observations from our study have relevant implications with respect to risk stratification of the population. First, our data underscore the importance of age ≥75, especially when combined with hypertension, as a prevalent and high-risk combination for both incident AF and incident stroke. In this particularly vulnerable and prevalent cohort, more proactive measures to screen for incident AF and other modifiable risk factors may be warranted. The use of longer-term, external electrocardiographic monitoring devices could provide a particular benefit in this population, especially if symptoms are present. Given that AF is underdiagnosed and may even present as incident stroke,26 earlier identification of subclinical AF in this high-risk cohort may permit earlier introduction of preventive measures, such as thromboprophylaxis where indicated. The value and optimal methodology for screening for AF in this cohort are incompletely understood and require further study. Second, our data challenge the present paradigm of risk prediction by addition, rather than combination. There is a need to develop new risk predictive models that account for the observed differential effects of specific combinations of risk factors. The ubiquity of computing and, increasingly, smartphone-based applications in modern medicine lowers the bar for clinical application of a more sophisticated combinatorial model. Such a combinatorial model could potentially offer a more individualized and accurate risk prediction for a given patient, with direct implications for consideration of more intensive monitoring and the use of preventive interventions. Limitations to our study include its retrospective design and its reliance on claims data. ICD-9 codes were used to ascertain diagnoses of AF and stroke, as well as risk factors and symptoms. There was likely variation in levels of arrhythmia monitoring and follow-up. In view of the acknowledged underdiagnosis of AF in the literature,26 ICD-9 coding used in our study may have underestimated the true incidence of AF. Similarly, patient risks could be underestimated, though this would have a conservative dampening effect on the risk differentials. Finally, MarketScan data consist only of insured patients and so are not representative of the uninsured population in the United States. Acknowledging these limitations, our study had multiple strengths, including its large, real-world sample and novel combinatorial approach. These advantages permit an important contribution to the body of literature on the prediction of AF and stroke and prompt new directions in public health strategies and research. Further, the annualized risks of AF and stroke associated with specific combinations of risk factors in our study provide clinicians with concrete estimates for individual patients in the clinic.

Conclusion

Adults with combinations of heart failure, hypertension, diabetes, advanced age (65 to 74 or ≥75), CAD, and CKD are at increased risks of incident AF and incident stroke. Risks associated with combinations of risk factors are not always additive. Rather, certain combinations of risk factors are associated with substantially higher risks of incident AF and incident stroke. The combination of age ≥75 and hypertension in particular is both prevalent and high risk, contributing substantially to the incidence of AF and the incidence of stroke, thus constituting an important target for more active monitoring and prevention.

Sources of Funding

This study was supported by Medtronic, Inc.

Disclosures

Dr. Chyou has no relationships relevant to the contents of this article to disclose. Dr. Hunter is an employee of CTI Clinical Trial and Consulting Services, which provides consulting services to Medtronic, plc. Ms. Mollenkopf is an employee of Medtronic, plc. Dr. Turakhia is a consultant to Medtronic, plc and St. Jude Medical, Inc and has received honoraria for speaking from St. Jude Medical, Inc and Boston Scientific. Dr. Reynolds is a consultant to Medtronic, plc.
  24 in total

1.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

Review 2.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jean-Yves Le Heuzey; G Neal Kay; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann
Journal:  J Am Coll Cardiol       Date:  2013-04-01       Impact factor: 24.094

3.  Temporal relationship between subclinical atrial fibrillation and embolic events.

Authors:  Michela Brambatti; Stuart J Connolly; Michael R Gold; Carlos A Morillo; Alessandro Capucci; Carmine Muto; Chu P Lau; Isabelle C Van Gelder; Stefan H Hohnloser; Mark Carlson; Eric Fain; Juliet Nakamya; Georges H Mairesse; Marta Halytska; Wei Q Deng; Carsten W Israel; Jeff S Healey
Journal:  Circulation       Date:  2014-03-14       Impact factor: 29.690

4.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

5.  Acute safety outcomes in younger and older patients with atrial fibrillation treated with catheter ablation.

Authors:  Steven C Hao; Tina D Hunter; Candace Gunnarsson; Jamie L March; Sarah A White; Joseph A Ladapo; Matthew R Reynolds
Journal:  J Interv Card Electrophysiol       Date:  2012-06-20       Impact factor: 1.900

6.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).

Authors:  C D Furberg; B M Psaty; T A Manolio; J M Gardin; V E Smith; P M Rautaharju
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

7.  Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study.

Authors:  Lloyd E Chambless; Gerardo Heiss; Eyal Shahar; Mary Jo Earp; James Toole
Journal:  Am J Epidemiol       Date:  2004-08-01       Impact factor: 4.897

8.  Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Authors:  Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf
Journal:  Circulation       Date:  2012-12-03       Impact factor: 29.690

9.  Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.

Authors:  R B D'Agostino; P A Wolf; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score.

Authors:  Daniel E Singer; Yuchiao Chang; Leila H Borowsky; Margaret C Fang; Niela K Pomernacki; Natalia Udaltsova; Kristi Reynolds; Alan S Go
Journal:  J Am Heart Assoc       Date:  2013-06-21       Impact factor: 5.501

View more
  9 in total

Review 1.  Transforming the care of atrial fibrillation with mobile health.

Authors:  Mintu P Turakhia; Daniel W Kaiser
Journal:  J Interv Card Electrophysiol       Date:  2016-06-15       Impact factor: 1.900

2.  Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Authors:  Yong-Ming Zhou; Ming-Jiang Li; Yan-Li Zhou; Le-Le Ma; Xin Yi
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Is Achieving the American Heart Association's Life Simple 7 Goals Sufficient to Reduce the Burden of Atrial Fibrillation? No Simple Answers.

Authors:  Pamela J McCabe; Dawood Darbar
Journal:  J Am Heart Assoc       Date:  2018-04-12       Impact factor: 5.501

4.  Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.

Authors:  Pooja Dewan; Pardeep S Jhund; Li Shen; Mark C Petrie; William T Abraham; M Atif Ali; Chen-Huan Chen; Akshay S Desai; Kenneth Dickstein; Jun Huang; Songsak Kiatchoosakun; Kee-Sik Kim; Lars Køber; Wen-Ter Lai; Yuhua Liao; Ulrik M Mogensen; Byung-Hee Oh; Milton Packer; Jean L Rouleau; Victor Shi; Antonio S Sibulo; Scott D Solomon; Piyamitr Sritara; Karl Swedberg; Hiroyuki Tsutsui; Michael R Zile; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2018-12-10       Impact factor: 15.534

5.  Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.

Authors:  Shaum M Kabadi; Ravi K Goyal; Saurabh P Nagar; James A Kaye; Keith L Davis
Journal:  Cancer Med       Date:  2019-05-29       Impact factor: 4.452

6.  Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.

Authors:  Shaum M Kabadi; Aimee Near; Keiko Wada; Chakkarin Burudpakdee
Journal:  Cancer Med       Date:  2019-10-08       Impact factor: 4.452

7.  Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.

Authors:  Ravi K Goyal; Saurabh P Nagar; Shaum M Kabadi; Hannah Le; Keith L Davis; James A Kaye
Journal:  Cancer Med       Date:  2021-03-18       Impact factor: 4.452

Review 8.  Atrial fibrillation in the elderly population: Challenges and management considerations.

Authors:  Mohammed Salih; Osama Abdel-Hafez; Ramzi Ibrahim; Rajiv Nair
Journal:  J Arrhythm       Date:  2021-06-24

Review 9.  Relationship between lipoproteins, thrombosis, and atrial fibrillation.

Authors:  Wern Yew Ding; Majd B Protty; Ian G Davies; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.